Targeting the CCL2/CCR2 axis, which plays a crucial role in recruiting monocytes in various cancer types such as pancreatic cancer [152], offers a promising therapeutic approach to hinder the recruitment of monocytes from the bone marrow into the bloodstream [153]. This evidence concerns the gene CCR2 and pancreatic neoplasm.